Fig. 6

Effect of doxorubicin and dox-MNV on HCC cells. HepG2, Hep3B, and PLC/PRF/5 HCC cells were treated with regular doxorubicin and dox-MNV at final concentrations of 500 and 750 nM for 72 h and assayed for cell viability. There was significant difference in the rate of cell death between regular doxorubicin and dox-MNV at 500 nM in the case of HepG2 and Hep3B cells (a). The difference was not significant at 750 nM (b). The data are mean ± SD (n = 8)